The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused more than 320 000 deaths as of May 19, 2020. COVID-19 deaths …

We read the Article by Thomas Huet and colleagues1 describing the effects of the
interleukin1 receptor antag onist anakinra in patients with severe COVID19 with great …

Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour
necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been …

Objectives Anakinra is a selective IL-1 inhibitor, which has been used in the context of
secondary haemophagocytic lymphohistiocytosis. Although usually given in the sc form …

Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently discovered
coronavirus, is responsible for COVID-19, a newly emerged disease that has become …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …

As of January, 2021, nearly 2-million deaths worldwide have been attributed to COVID-19,
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Much …

COVID-19 is characterized by a wide range of clinical manifestations that may become
severe by progressing towards acute respiratory distress syndrome and death [1]. After an …

In a subgroup of patients, severe acute respiratory syndrome corona virus 2 (SARSCoV2)
induces a hyper inflammatory response that leads to acute respiratory dis tress syndrome. 1 …